SynthesisAdvances in therapy2015
Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.
Synthesis in Advances in therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Pooled it
- Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.Clinical and vaccine immunology : CVI · 2015Trial
- Population-Level Impact of Human Papillomavirus Vaccination on the Incidence of Genital Warts in Sweden.The Journal of infectious diseases · 2025Article
- Article
- Optimizing HPV vaccine effectiveness: impact of vaccination age and dose schedule on immunogenicity and cervical cancer prevention.Frontiers in public health · 2025Review
- Assessing Saudi women's awareness about human papillomavirus (HPV) and their susceptibility to receive the vaccine.Human vaccines & immunotherapeutics · 2024Article
- Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types.PloS one · 2024Article
- Human Papilloma Virus: An Unraveled Enigma of Universal Burden of Malignancies.Pathogens (Basel, Switzerland) · 2023Review
- Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Observational
- An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy.Frontiers in immunology · 2021Review
- Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).BMC infectious diseases · 2020Article
- Addressing HPV vaccine myths: practical information for healthcare providers.Human vaccines & immunotherapeutics · 2019Review
- Review
- Article
- Prevalence and incidence of external genital warts in a sample of Italian general female population.BMC infectious diseases · 2017Article
- Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.PloS one · 2017Article
- Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.BMC infectious diseases · 2016Article
- Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2016Review
- Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSince 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.
methodsWe performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.
resultsA total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged <21 years who reported being vaccinated. A 92.6% reduction in GWs incidence was reported for all women in this age group, where the vaccine uptake rate (VUR) was 70% for 3 doses. The highest reductions were reported in countries with high VURs, mostly through school-based vaccination programs, although high VURs were obtained with some non-school-based programs.
conclusionThe results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.